Media coverage about Organovo (NASDAQ:ONVO) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Organovo earned a media sentiment score of 0.00 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 46.9888505792381 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern’s analysis:
- You Need To Taste These: Repligen Corporation (NASDAQ:RGEN), Organovo Holdings, Inc. (NASDAQ:ONVO), Turtle … (thestreetpoint.com)
- Traders can’t blink on these Mid-Day Stocks: Organovo Holdings, Inc. (NASDAQ:ONVO), Yulong Eco-Materials Limited … (journalfinance.net)
- Analysis and Stocks Valuation: Organovo Holdings, Inc. (NASDAQ:ONVO), Dover Downs Gaming & Entertainment, Inc … (journalfinance.net)
- Zacks: Brokerages Anticipate Organovo Holdings Inc (ONVO) Will Post Quarterly Sales of $900,000.00 (americanbankingnews.com)
- Zacks: Brokerages Anticipate Organovo Holdings Inc (ONVO) to Post -$0.08 EPS (americanbankingnews.com)
Shares of ONVO traded down $0.03 during midday trading on Thursday, reaching $1.24. 8,950 shares of the company were exchanged, compared to its average volume of 630,645. The stock has a market cap of $146.35 million, a PE ratio of -3.88 and a beta of 2.78. Organovo has a 1-year low of $0.91 and a 1-year high of $2.38.
Organovo (NASDAQ:ONVO) last issued its quarterly earnings data on Thursday, August 9th. The medical research company reported ($0.07) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.07). The company had revenue of $0.69 million for the quarter, compared to analysts’ expectations of $1.16 million. Organovo had a negative return on equity of 68.85% and a negative net margin of 746.56%. analysts predict that Organovo will post -0.29 EPS for the current year.
A number of research analysts recently weighed in on ONVO shares. Jefferies Financial Group reiterated a “buy” rating and issued a $1.75 target price on shares of Organovo in a report on Friday, July 27th. Zacks Investment Research upgraded Organovo from a “sell” rating to a “hold” rating in a report on Saturday, September 1st. Finally, ValuEngine upgraded Organovo from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $2.75.
Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Article: Google Finance Portfolio Workaround
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.